Emerging therapeutic agents for advanced non-small cell lung cancer

被引:256
作者
Chen, Ruqin [1 ]
Manochakian, Rami [1 ]
James, Lauren [1 ]
Azzouqa, Abdel-Ghani [1 ]
Shi, Huashan [1 ]
Zhang, Yan [1 ]
Zhao, Yujie [1 ]
Zhou, Kexun [1 ]
Lou, Yanyan [1 ]
机构
[1] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA
关键词
Advanced non-small cell lung cancer; NSCLC; Emerging therapeutic agents; Targeted therapy; Immunotherapy; Clinical trials; PEMETREXED PLUS CISPLATIN; DRUG CONJUGATE ADC; PATIENTS PTS; OPEN-LABEL; PHASE-II; SOLID TUMORS; DOSE-ESCALATION; CLINICAL ACTIVITY; NSCLC PATIENTS; SINGLE-ARM;
D O I
10.1186/s13045-020-00881-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances in targeted therapy and immunotherapy have changed the landscape for the treatment of advanced NSCLC. In the last 10 years, the US Food and Drug Administration (FDA) has approved more than 17 new medications for this devastating disease and more are coming. Molecular and immunogenic testing makes personalized medicine possible for patients with advanced NSCLC. The new medications provide promising efficacy and safety resulting in improved long-term survival for a significant number of patients. In this review, we summarize the recent advances in advanced/metastatic NSCLC therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to current standard drugs in the same class or are a completely new class of drugs with novel mechanisms of action. Advances are divided into (1) targeted agents, (2) antibody-drug conjugates, and (3) immunotherapies. Finally, we present a brief review of the emerging agents and ongoing clinical studies.
引用
收藏
页数:23
相关论文
共 129 条
[1]   Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies. [J].
Adjei, Alex A. ;
Bekaii-Saab, Tanios S. ;
Berlin, Jordan ;
Philip, Agop Philip ;
Mercade, Teresa Macarulla ;
Walter, Annette ;
Cupit, Lisa ;
Liu, Rong ;
Fields, Scott Z. ;
Holynskyj, Ariadna .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2]  
Ahn MJ, 2019, J CLIN ONCOL, V37
[3]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[4]   AACR Project GENIE: Powering Precision Medicine through an International Consortium [J].
Andre, Fabrice ;
Arnedos, Monica ;
Baras, Alexander S. ;
Baselga, Jose ;
Bedard, Philippe L. ;
Berger, Michael F. ;
Bierkens, Mariska ;
Calvo, Fabien ;
Cerami, Ethan ;
Chakravarty, Debyani ;
Dang, Kristen K. ;
Davidson, Nancy E. ;
Del Vecchio, Fitz Catherine ;
Dogan, Semih ;
DuBois, Raymond N. ;
Ducar, Matthew D. ;
Futreal, P. Andrew ;
Gao Jianjiong ;
Garcia, Francisco ;
Gardos, Stu ;
Gocke, Christopher D. ;
Gross, Benjamin E. ;
Guinney, Justin ;
Heins, Zachary J. ;
Hintzen, Stephanie ;
Horlings, Hugo ;
Hudecek, Jan ;
Hyman, David M. ;
Kamel-Reid, Suzanne ;
Kandoth, Cyriac ;
Kinyua, Walter ;
Kumari, Priti ;
Kundra, Ritika ;
Ladanyi, Marc ;
Lefebvre, Celine ;
LeNoue-Newton, Michele L. ;
Lepisto, Eva M. ;
Levy, Mia A. ;
Lindeman, Neal, I ;
Lindsay, James ;
Liu, David ;
Lu Zhibin ;
MacConaill, Laura E. ;
Ian, Maurer ;
Maxwell, David S. ;
Meijer, Gerrit A. ;
Meric-Bernstam, Funda ;
Micheel, Christine M. ;
Miller, Clinton ;
Mills, Gordon .
CANCER DISCOVERY, 2017, 7 (08) :818-831
[5]  
[Anonymous], 2019, J CLIN ONCOL S
[6]  
[Anonymous], 2019, J CLIN ONCOL S
[7]  
[Anonymous], 2018, ONCOLOGY PRO
[8]  
[Anonymous], 1 HUMAN PHASE 1 2 TR
[9]  
[Anonymous], 2017, ANN ONCOL
[10]  
[Anonymous], 2019, CLIN ONCOL S